Valneva SE

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

04 дек 2023 00:00:00 Источник Nasdaq GlobeNewswire

EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

27 ноя 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

15 ноя 2023 00:30:00 Источник Nasdaq GlobeNewswire

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

10 ноя 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

09 ноя 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 ноя 2023 00:00:00 Источник Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2023

06 ноя 2023 01:30:00 Источник Nasdaq GlobeNewswire

Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment

25 окт 2023 11:15:00 Источник Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

11 окт 2023 10:45:00 Источник Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: September 30, 2023

05 окт 2023 01:30:00 Источник Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

25 сен 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

21 сен 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07 сен 2023 00:00:00 Источник Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: August 31, 2023

06 сен 2023 01:30:00 Источник Nasdaq GlobeNewswire

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

31 авг 2023 12:00:00 Источник Nasdaq GlobeNewswire

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

29 авг 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

28 авг 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Announces Extension of Existing Loan Agreement

17 авг 2023 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

14 авг 2023 00:00:00 Источник Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - July 31, 2023

03 авг 2023 01:30:00 Источник Nasdaq GlobeNewswire